US Patent

US10813976 — Ophthalmic compositions comprising ciclosporin

Formulation · Assigned to Novaliq GmbH · Expires 2037-09-22 · 11y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects ophthalmic compositions that are clear solutions of ciclosporin with low residual water content and 1-perfluorobutylpentane for topical eye administration.

USPTO Abstract

The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.

Drugs covered by this patent

Patent Metadata

Patent number
US10813976
Jurisdiction
US
Classification
Formulation
Expires
2037-09-22
Drug substance claim
No
Drug product claim
Yes
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.